ACE DD genotype: An independent predisposition factor to venous thromboembolism

European Journal of Clinical Investigation

Volumn 33, Issue 8, 2003, Pages 642-647

  Fatini, C ^a   Gensini, F ^a   Sticchi, E ^a   Battaglini, B ^a   Prisco, D ^a   Fedi, S ^a   Brunelli, T ^a   Marcucci, R ^a   Conti, A A ^a,b,c   Gensini, G F ^a,b,c   Abbate, Rossana ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Centro S Maria degli Ulivi   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

ACE gene; AT1R gene; Polymorphism; Thrombophilia; Venous thromboembolism

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; DIPEPTIDYL CARBOXYPEPTIDASE; DNA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA DETERMINATION; ENZYME ANALYSIS; FEMALE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA; VEIN THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CYSTEINE; FACTOR V; FEMALE; GENOTYPE; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; MUTATION; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROTHROMBIN; RISK FACTORS; VENOUS THROMBOSIS;

EID: 0042666940     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2003.01185.x     Document Type: Article

References (31)

1. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992;232:155-60.
2. Bertina RM, Koeleman BP, Koster T, Rosendaal F, Dirven RJ, de Ronde H. Mutation in blood coagulation Factor V associated with resistance to activate protein C. Nature 1994;369:64-7.
3. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
4. Fermo I, Viganò D'Angelo S, Paroni R, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinaemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med 1995;123:747-53.
5. Pabinger I, Brucker S, Kyrle PA, Schneider B, Korninger HC, Niessner H et al. Hereditary deficiency of antithrombin III, protein C and protein S. prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992;3:547-53.
6. Bertina RM, Reitsm PH, Rosendaal FR, Vandenbroucke JP. Resistance to activated protein C and Factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 1995;74:449-53.
7. Nishimura H, Tsuji H, Masuda H, Kasahara T, Yoshizumi M, Sugano T et al. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb Haemost 1999;82:1516-21.
8. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin-converting enzyme gene (DCP1) (dipeptidyl carboxypeptidase 1). Nucl Acids Res 1992;20:1433.
9. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
10. Paxton WG, Runge M, Horaist C, Cohen C, Alexander RW, Bernstein KE. Immunohistochemical localization of rat angiotensin II AT1 receptor. Am J Physiol 1993;264:F989-95.
11. Katsuja T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R et al. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet 1995;345:1660-3.
12. Fatini C, Abbate R, Pepe G, Battaglini B, Gensini F, Ruggiano G et al. Searching for a better assessment of the individual coronary risk profile. The role of angiotensin-converting enzyme, angiotensin II type 1 receptor and angiotensinogen gene polymorphisms. Eur Heart J 2000;21:633-8.
13. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A et al. Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 1994;344:910-3.
14. Bonnardeaux A, Davies E, Jeunemaitre X, Fery I, Charru A, Clauser E et al. Angiotensin II type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 1994;24:63-9.
15. Philipp CS, Dilley A, Saidi P, Evatt B, Austin H, Zawadsky J et al. Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 1998;80:869-73.
16. Dilley A, Austin H, Craig Hooper W, Lally C, Kibeiro MJA, Wengher NK et al. Relation of three genetic traits to venous thrombosis in an African-American population. Am J Epidemiol 1998;147:30-5.
17. Hooper WC, Bowling NF, Wenger NK, Dilley A, Ellingsen D, Evatt BL. Relationship of venous thromboembolism and myocardial infarction with the renin angiotensin system in African-Americans. Am J Hematol 2002;70:1-8.
18. Gonzalez Ordonez AJ, Fernandez Carreira JM, Medina Rodriguez JM, Martin Sanchez L, Alvarez Diaz R, Alvarez Martinez MV et al. Risk of venous thromboembolism associated with the insertion/deletion polymorphism in the angiotensin-converting enzyme gene. Blood Coagul Fibrinolysis 2000;11:485-90.
19. Jackson A, Brown K, Langdown J, Luddington R, Baglin T. Effect of the angiotensin-converting enzyme gene deletion polymorphism on the risk of venous thromboembolism. Br J Haematol 2000;111:562-4.
20. Della Valle CJ, Issack PS, Baitner A, Steiger DJ, Fang C, Di Cesare PE. The relationship of the Factor V Leiden mutation or the deletion-deletion polymorphism of the angiotensin-converting enzyme to postoperative thromboembolic events following total joint arthroplasty. BMC Musculoskeletal Disorders 2001;2:1-6.
21. Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai AP et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001;86:772-6.
22. Boers G, Smals AGH, Trijbels FJM, Fowler B, Bakkeren JAJM, Schoonderwaldt HC et al. Heterozygosity for homocystinuria in premature peripheral and cerebral occlusive arterial disease. N Engl J Med 1985;313:709-15.
23. Ribichini F, Steffino G, Dellavalle A, Matullo G, Colajanni E, Camilla T et al. Plasma activity and insertion/deletion polymorphism of angiotensin I-converting enzyme. A major risk factor and a marker of risk for coronary stent restenosis. Circulation 1998;97:147-54.
24. Kraaijenhagen RA, in 't Anker PS, Koopman MMW, Reitsma PH, Prins MH, van den Ende A et al. High plasma concentration of Factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5-9.
25. Meijiers J, Tekelenburg WLH, Bouma BN, Bertina RM, Rosendaal FR. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 2000;342:696-701.
26. van Hylckama Vlieg A, van der Linden IK, Bertina RM, Rosendaal FR. High levels of factor IX increase the risk of venous thrombosis. Blood 2000;95:3678-82.
27. Rakugi H, Kim DK, Krieger JE, Wang DS, Dzau VJ. Induction of angiotensin-converting enzyme in the neointima after vascular iniury: possible role in restenosis. J Clin Invest 1994;93:339-46.
28. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995;95:995-1001.
29. Vaughan DE. Fibrinolytic balance, the renin-angiotensin system and atherosclerotic disease. Eur Heart J 1998;19 (Suppl. G):G9-12.
30. Zurbano MJ, Anguera I, Heras M, Roig E, Lozano M, Sanz G et al. Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIIa in early postmyocardial infarction stage. Arterioscler Thromb Vasc Biol 1999;19:1791-5.
31. Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997;77:1189-95.